Search Results 101-110 of 13527 for Relaxin-2
Contact the study team to discuss study eligibility and potential participation. Show more eligibility criteria. Inclusion Criteria: 1. Age \>18 years of age 2.
Twelve eligible subjects will be randomly assigned to receive Glucagon RTU or placebo at the first of two clinical research center (CRC) visits, followed by the ...
... 2 focuses on primary or secondary myelofibrosis (MF) displaying mutated ... (2-4) advanced, unresectable breast cancer (up to 6 donors per phenotype ...
... 2, and 6); OR; At least one 4-week induction regimen of adalimumab (one 160 mg subcutaneous [SC] dose at Baseline, followed by one 80 mg SC dose at Week 2 ...
Currently or previously (during the past 2 months) participation in any other research study at the discretion of study personnel. Blood/plasma donation ...
This phase I/II trial studies the side effects and best dose of romidepsin and lenalidomide when combined with rituximab and to see how well this combination ...
Clinical Trials · A 2-Year, Open-Label, Safety Extension Study Of Gevokizumab In Subjects With Pyoderma Gangrenosum · More about research at Mayo Clinic · Mayo ...
1/2. During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3) ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Mayo Clinic researchers drive discoveries that improve detection, diagnosis and treatment. Your quick message to them means so much.